# \[e-drug\] Banning metamisole in Moldova (5) **URL:** \ **Category:** e-drug\ **Created:** [January 17, 2002, 7:54pm UTC](https://talk.edrugplus.org/t/e-drug-banning-metamisole-in-moldova-5/13419 "2002-01-17T19:54:58Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![Vladimir\_S\_Shoukhov](https://avatars.discourse-cdn.com/v4/letter/v/e19b73/32.png) [@Vladimir\_S\_Shoukhov](https://talk.edrugplus.org/u/Vladimir_S_Shoukhov)\ **Post date:** [January 17, 2002, 7:54pm UTC](https://talk.edrugplus.org/t/e-drug-banning-metamisole-in-moldova-5/13419/1 "2002-01-17T19:54:58Z")
E-drug: Banning metamisole in Moldova (5) ------------------------------------------------------------ Dear Natalia, This is a remark from Dr.Herxheimer, had been sent more then a two years ago. But it is still relevant to this question. Prof. Vladimir S. Shoukhov, M.D., D.Sci (Med) +7 (095) 930 4105 shoukhov@yahoo.com April 1999 The following question and answer will interest e-druggers. Andrew Herxheimer Andrew\_Herxheimer@compuserve.com DIPYRONE (METAMIZOL): RESTORED TO GOOD REPUTE ? translated from: P.S. Schonhofer: Internistische Praxis 1999; 39: 184-185 Question: Dipyrone (NOVALGIN etc.) has been re-licensed without restrictions in Sweden. What implications does this have in Germany? Answer: 1. The licensed indications for dipyrone in Germany have not changed since 1986. There is no recent new scientific evidence affecting the state of knowledge. The licensed indications are: a) acute severe pain due to trauma or surgery, b) colic pain, c) cancer pain or other severe acute or chronic pain, but only if other therapeutic interventions have failed or are contra-indicated, d) severe hyperpyrexia, when other measures have failed. Therefore, dipyrone is not licensed for pain such as migraine headache, since other non-opioid analgesics (acetylsalicylic acid, paracetamol or naproxen) are equally effective and other drugs are even superior, such as sumatriptan or ergotamine. Dipyrone is also not to be considered a substitute for acetylsalicylic acid, paracetamol or diclofenac in the WHO-guideline for control of pain, since it poses a higher risk to the patient than the other drugs at equieffective doses. The regulations of the German drug law are not invalidated by claims of 'therapeutic freedom' made by the medical profession. The attending physician who has used dipyrone outside the approved indications is legally liable in cases of suspected drug- induced damage. The onus is on the physician, not the patient, to prove that the therapeutic choice was appropriate. This is difficult to achieve, especially since few data appear to exist to show that dipyrone is more effective or safer than other non-opioid analgesics. 2. The producer of dipyrone and some scientific advisers have repeatedly stated that the risk of developing agranulocytosis due to dipyrone is as low as 1:1 million. This is misleading and false. The results from the IAAAS (International Agranulocytosis and Aplastic Anemia Study) (5) give as dimension of the denominator "1 week of use", while the incidence of agranulocytosis is usually given as cases per year. So one has to multiply the incidence of dipyrone- induced agranulocytosis in the IAAAS (1:1 million) by 52 (weeks) in order to obtain the correct units (year). This gives the figure of 1 case of agranulocytosis in 20,000 users of dipyrone per year (1:20,000), a realistic value. In 1985 the IAAAS documented about 100 cases of dipyrone- Induced agranulocytosis in the Federal Republic of Germany. The use of dipyrone was close to 10 million packages prescribed for about 3 million patients in the same year. This gives 1 case of agranulocytosis in 30,000 users (1:30,000). This value is in agreement with data calculated from the international literature by the Federal Health Office in 1982 (1). Both calculations show that the risk of dipyrone-induced agranulocytosis is in fact about 50-fold higher than the "weekly" risk dimension of 1: 1 million described by the IAAAS (5) and widely propagated by the producer. 3. Dipyrone is a highly immunogenic compound. It not only causes allergic reactions in the bone marrow but also the whole spectrum of severe immunogenic diseases including interstitial nephritis, hepatitis, alveolitis, and pneumonitis as well as severe skin diseases such as Lyell or Stevens-Johnson syndrome (2). Dipyrone often causes vasculitis which clinically presents as shock-syndrome of acute or delayed onset. Data from our hospital-based adverse drug reactions monitoring system suggest that dipyrone-induced shock reactions of the vasculitis type occur about 10 times more often than agranulocytosis. The mortality of this reaction appears to be about 30-50 % in our patients: both substitution of volume and vasoconstrictor measures fail to raise blood pressure due to the destruction of the vascular endothelial cells by the dipyrone-induced hypersensitivity vasculitis. This dimension of the risks induced by dipyrone is neither published nor discussed by producers or users (4), even though information is available on the high risks for many immunogenic diseases in addition to agranulocytosis (2). 4. It cannot be argued that dipyrone was re-licensed in Sweden, since the Swedish authorities wanted to revise a false evaluation of the risks of the drug in 1973 (3). The clinician who described the special risk of agranulocytosis by dipyrone in Sweden is no longer professionally active. On the other hand, the head of the department of drug safety in the Swedish drug agency appears to be close to the interests of the main dipyrone producer Hoechst which can be inferred from his participation in the IAAAS. It appears strange that a responsible official of a drug regulatory office is allowed to participate in projects sponsored by the pharmaceutical industry and to profit in his scientific career from such support. Suspected similar activities caused the resignation even of the president of the German Federal Health Office (BGA) in the mid-eighties. References: 1. Anonymous. Dipyrone Hearing of the German Drug Authority. Lancet 1986;II: 737. 2. A.T.I. Arzneimittelinformation: Vom Verdacht zur Diagnose, 2. Aufl., S. 5-14. Berlin 1998. 3. Boettiger LE, Westerholm B. Drug-induced blood dyscrasia in Sweden. Br.med. J. 1973;III:339-343. 4. Gericke D. Editorial: Eindrucksvolles Comeback. Munch.med.Wschr. 1997; 139:110. 5. Kaufmann DW et al. The Drug Epidemiology of Agranulocytosis and Aplastic Anemia. Monographs in Epidemiology and Statistics, Vol.18. Oxford University Press 1991. Prof Dr. P.S. Schonhofer Institute of Clinical Pharmacology ZKH Sankt-Jorgen-Strasse D-28205 Bremen, GERMANY e-mail: klin.pharm@zkhstjuergen.bremen.de -- To send a message to E-Drug, write to: e-drug@usa.healthnet.org To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org in the body of the message type: subscribe e-drug OR unsubscribe e-drug To contact a person, send a message to: owner-e-drug@usa.healthnet.org Information and archives: [http://www.healthnet.org/programs/edrug.html](http://www.healthnet.org/programs/edrug.html)